News
-
MIMS partners with CareRight
Wednesday | May 3 2017THE CareRight medical specialist software platform provided by Clintel has gone live with a full integration of the MIMS Medicines Data Base and Evidence Based Decision Support a key part of the browser-based system.
-
GSK 2016 results
Wednesday | May 3 2017GLAXOSMITHKLINE'S pharmaceuticals and vaccines business in Australia recorded almost $1 billion in revenue last year, with a pre-tax profit of $47m.
-
Medical cannabis here
Wednesday | May 3 2017THE first shipments of medical cannabis products to be imported into Australia under new legislation have arrived in Perth.
-
Generics opt-out flagged
Wednesday | May 3 2017NEXT week's federal budget will see significant changes to the way medications are prescribed in Australia, with generic versions of drugs to be the default option in doctors prescribing software.
-
May PBS additions
Tuesday | May 2 2017HEALTH minister Greg Hunt yesterday confirmed the addition of "$310 million of new vital drugs" to the Pharmaceutical Benefits Scheme, with new items including Kalydeco (ivacaftor) for children aged 2-5 with cystic fibrosis.
-
New MSD biosimilar
Tuesday | May 2 2017RENFLEXIS from the MSD stable is the second infliximab biosimilar to be given TGA approval, and the company is planning a hospital launch of the product in 2017.
-
Winter is (nearly) here
Tuesday | May 2 2017TODAY'S issue of Pharmacy Daily features our newest Spotlight supplement, with details of several products ideal for winter sales included on page three.
-
Mayne loses $200m
Tuesday | May 2 2017MAYNE Pharma shares fell almost 11% on Mon, wiping around $200m from its market capitalisation, following a revelation that sales for its Teva suite of US generic products would not meet forecasts.
-
$10m for myDNA
Tuesday | May 2 2017MELBOURNE-BASED myDNA has raised $10 million in its latest round of capital raising, which has included the backing of Swisse ceo Radek Sali who is joining the genetics company's board.